机构：[1]Department of Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China[2]Criminal Science and Technology Office in Criminal Police Brigade of Pidu Branch of Chengdu Public Security Bureau, Chengdu, China[3]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China四川省肿瘤医院
Objective: Heat shock protein 90 alpha (HSP90 alpha) is associated with cancer development, progression, and metastasis. This study assessed the relationships of plasma HSP90 alpha levels with treatment efficacy and prognosis in lung cancer. Methods: In this retrospective cross-sectional study, 231 patients with lung cancer were enrolled from 1 September 2016 to 31 December 2019. HSP90 alpha levels were measured before and after treatment, and their relationships with outcomes were assessed. Results: Patients with elevated HSP90 alpha levels before treatment had a better overall response rate (ORR, 44.1% vs. 30.6%), whereas the disease control rate did not differ between patients with elevated and normal HSP90 alpha levels (81% vs. 78.5%). Median progression-free survival (PFS) was 6.9 months in patients with elevated baseline HSP90 alpha levels, versus 9 months in patients with normal HSP90 alpha levels, whereas the median overall survival (OS) times in these groups were 12 and 14.1 months, respectively. Concerning HSP90 alpha levels after treatment, ORR (20% vs. 47.1%) and DCR (67.3% vs. 90.9%) were lower in patients with increased HSP90 alpha levels, and PFS and OS were also significantly different between the groups. Conclusions: HSP90 alpha levels before and after treatment were associated with treatment response and patient prognosis in lung cancer.
基金：
Lian Yun Gang Shi
Hui Lan Public Foundation (HL-HS2020-7),
the Foundation of Science and Technology
Department of Sichuan Province (2019YJ0583,
2020YFS0421), and the Sichuan Science and
Technology Innovation Seedling Project
(2021040).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
最新[2023]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
JCR分区：
出版当年[2021]版：
Q4MEDICINE, RESEARCH & EXPERIMENTALQ4PHARMACOLOGY & PHARMACY
最新[2023]版：
Q4MEDICINE, RESEARCH & EXPERIMENTALQ4PHARMACOLOGY & PHARMACY
第一作者机构：[1]Department of Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
共同第一作者：
通讯作者：
通讯机构：[3]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China[*1]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province 610041, China.
推荐引用方式(GB/T 7714)：
Xiaoqian Li,Xuesong Tong,Bin Liu,et al.Potential predictive value of plasma heat shock protein 90 alpha in lung cancer[J].JOURNAL OF INTERNATIONAL MEDICAL RESEARCH.2021,49(12):doi:10.1177/03000605211064393.
APA：
Xiaoqian Li,Xuesong Tong,Bin Liu,Zeng Li,Jing Ding...&Jun Ge.(2021).Potential predictive value of plasma heat shock protein 90 alpha in lung cancer.JOURNAL OF INTERNATIONAL MEDICAL RESEARCH,49,(12)
MLA：
Xiaoqian Li,et al."Potential predictive value of plasma heat shock protein 90 alpha in lung cancer".JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 49..12(2021)
